AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2024

Mar 12, 2024

32973_dirs_2024-03-12_10dd2bce-4fac-46af-9a98-6ea79bec5d7f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2024-03-11

Reporting Person: Schall Thomas J. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-03-11	Stock Option	$5.93	A	35000	Acquired	2034-03-11	Class A Common Stock (35000)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on April 11, 2024, and will be fully vested and exercisable on March 11, 2027.